<DOC>
	<DOCNO>NCT02984930</DOCNO>
	<brief_summary>The gastric acid pocket believe reservoir acid reflux event originate . The risk acidic reflux mainly determine position gastric acid pocket . Little known change position size acid pocket contribute therapeutic effect proton pump inhibitor ( PPI ) plus mosapride patient gastroesophageal reflux disease . Investigators conduct prospective randomize , single blind placebo-controlled clinical trial evaluate hypothesis mosapride affect gastric motility might reduce gastro-esophageal reflux change acid pocket position size .</brief_summary>
	<brief_title>Effect Proton Pump Inhibitor Mosapride Acid Pocket Gastroesophageal Reflux Disease</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Mosapride</mesh_term>
	<criteria>Patients diagnose GERD ( gastroesophageal reflux disease ) , define presence oesophagitis obtain previous upper endoscopy typical GERD symptom ( heartburn , acid reflux ) . organic gastrointestinal disease include inflammatory bowel disease , cancer ulcer take drug could affect evaluation treatment ; PPIs , H2RAs ( H2 receptor antagonist ) , prokinetics , mucosal protective agent , antacid , cholinergic anticholinergic agent , antidepressant least 4 week prior study start severe systemic disease include hepatic nephrotic disease previous gastrectomy history state pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>